Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

White-collar lawyer and former U.S. attorney Neil MacBride has rejoined Davis, Polk & Wardwell following a two-year stint as ...

Bariatric surgery significantly reduced long-term risk for decompensation and adverse outcomes in patients with obesity and ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...

At the Capability Leaders Forum, marketers from AstraZeneca, Reckitt and Trainline discussed the potential of genAI to ...

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...